NCT04676945 is a clinical trial in Myelodysplastic Syndromes, sponsored by Michael Pfeilstöcker.

Who is sponsoring NCT04676945?

NCT04676945 is sponsored by Michael Pfeilstöcker.

What condition does NCT04676945 study?

NCT04676945 studies Myelodysplastic Syndromes.

Is NCT04676945 still recruiting?

NCT04676945 is currently completed. Last updated 22 November 2022.

Last reviewed 2022-11-22 · How we verify

NCT04676945

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Analysis of Risk in MDS Over Time - Comparison of Treated vs Untreated Patients

Completed Last updated 22 November 2022

What this trial tests

trial in Myelodysplastic Syndromes in 9,179 participants. Completed in 21 November 2022.

Timeline

21 August 2020

Primary endpoint
20 August 2021

21 November 2022

Quick facts

Lead sponsor	Michael Pfeilstöcker
Status	Completed
Study type	OBSERVATIONAL
Enrollment	9,179
Start date	21 August 2020
Primary completion	20 August 2021
Estimated completion	21 November 2022
Sites	1 location across Austria

Conditions studied

Myelodysplastic Syndromes — all drugs for Myelodysplastic Syndromes →

Sponsor

Michael Pfeilstöcker

Who can join

Eligibility, any sex, with Myelodysplastic Syndromes. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

A comparison of treated vs untreated patients with MDS with a sample size of approximately 8000 patients in 11 countries.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Myelodysplastic Syndromes

Currently open trials in the same condition.

NCT07566377 — Cord Blood Transplantation in Children and Young Adults With Blood Cancer · Phase 2 · recruiting
NCT06303193 — Pacritinib, a Kinase Inhibitor of CSF1R, IRAK1, JAK2, and FLT3, in Adults and Pediatric Participants 12 Years of Age or · Phase 1, PHASE2 · recruiting
NCT07071155 — Momelotinib in Combination With Hypomethylating Agent for Chronic Phase Myelodysplastic Syndromes/Myeloproliferative Ove · EARLY_PHASE1 · recruiting
NCT07283900 — Ascorbate in Myelodysplastic Syndrome · Phase 2 · recruiting
NCT06487247 — HEME Home Transfusion Program · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04676945 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Michael Pfeilstöcker
Last refreshed: 22 November 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04676945.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing